c-Cbl regulates MICA-but not ULBP2-induced NKG2D down-modulation in human NK cells

European Journal of Immunology

Volumn 44, Issue 9, 2014, Pages 2761-2770

  Molfetta, Rosa ^a   Quatrini, Linda ^a   Capuano, Cristina ^b   Gasparrini, Francesca ^a,c   Zitti, Beatrice ^a   Zingoni, Alessandra ^a   Galandrini, Ricciarda ^b   Santoni, Angela ^a,b   Paolini, Rossella ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Endocytosis; NK cells; NKG2D ligands; NKG2D receptor

Indexed keywords

CBL PROTEIN; CBL PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HLA ANTIGEN CLASS 1; KLRK1 PROTEIN, HUMAN; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; NATURAL KILLER CELL RECEPTOR NKG2D; SIGNAL PEPTIDE; UBIQUITIN; ULBP2 PROTEIN, HUMAN;

ARTICLE; CELL LINE; DOWN REGULATION; ENDOCYTOSIS; HUMAN; IMMUNOLOGY; NATURAL KILLER CELL; NK CELLS; NKG2D LIGANDS; PROTEIN DEGRADATION;

ENDOCYTOSIS; NK CELLS; NKG2D LIGANDS; NKG2D RECEPTOR;

CELL LINE; DOWN-REGULATION; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-CBL; UBIQUITIN;

EID: 84907835076     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444512     Document Type: Article

References (55)

1. Lanier, L. L., NK cell recognition. Annu. Rev. Immunol. 2005. 23: 225-274.
2. Tassi, I., Klesney-Tait, J. and Colonna, M., Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunol. Rev. 2006. 214: 92-105.
3. Long, E. O., Sik Kim, H., Liu, D., Peterson, M. E. and Rajagopalan, S., Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 2013. 31: 227-58.
4. Raulet, D. H., Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003. 3: 781-790.
5. Burgess, S. J., Maasho, K., Masilamani, M., Narayanan, S., Borrego, F. and Coligan, J. E., The NKG2D receptor: immunobiology and clinical implications. Immunol. Res. 2008. 40: 18-34.
6. Champsaur, M. and Lanier, L. L., Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 2010. 235: 267-285.
7. Raulet, D. H., Gasser, S., Gowen, B. G., Deng,W. and Jung, H., Regulation of Ligands for the NKG2D Activating Receptor. Annu. Rev. Immunol. 2013. 31: 413-441.
8. Lanier, L. L., A renaissance for the tumor immunosurveillance hypothesis. Nat. Med. 2001. 7: 1178-1180.
9. Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P. et al., Regulation of cutaneous malignancy by gammadelta T cells. Science 2001. 294: 605-609.
10. Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M. and Hayakawa, Y., NKG2D function protects the host from tumor initiation. J. Exp. Med. 2005. 202: 583-588.
11. Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S. et al.,NKG2D-deficientmice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008. 28:571-580.
12. Zafirova, B., Mandarić, S., Antulov, R., Krmpotić, A., Jonsson, H., Yokoyama, W. M., Jonjić, S. et al., Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity 2009. 31: 270-282.
13. Eagle, R. A. and Trowsdale, J., Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 2007. 7: 737-744.
14. Nausch, N. and Cerwenka, A., NKG2D ligands in tumor immunity. Oncogene 2008. 27: 5944-5958.
15. Raulet, D. H. and Guerra, N., Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 2009. 9: 568-580.
16. López-Larrea, C., Suárez-Alvarez, B., López-Soto, A., López-Vázquez, A. and Gonzalez, S., The NKG2D receptor: sensing stressed cells. Trends Mol. Med. 2008. 14: 179-189.
17. El-Gazzar, A., Groh, V. and Spies, T., Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J. Immunol. 2013. 191: 1509-1515.
18. Salih, H. R., Holdenrieder, S. and Steinle, A., Soluble NKG2D ligands: prevalence, release, and functional impact. Front. Biosci. 2008. 13: 3448- 3456.
19. Groh, V., Wu, J., Yee, C. and Spies, T., Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002. 419: 734-738.
20. Doubrovina, E. S., Doubrovin, M. M., Vider, E., Sisson, R. B., O'Reilly, R. J., Dupont, B. andVyas, Y. M., Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 2003. 171: 6891-6899.
21. Ogasawara, K., Hamerman, J. A., Hsin, H., Chikuma, S., Bour-Jordan, H., Chen, T., Pertel, T. et al., Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003. 18: 41-51.
22. Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M. et al., Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 2005. 6: 928-937.
23. Wiemann, K., Mittrücker, H. W., Feger, U., Welte, S. A., Yokoyama, W. M., Spies, T., Rammensee, H. G. et al., Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 2005. 175: 720- 729.
24. Coudert, J. D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E. and Held, W., Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005. 106: 1711-1717.
25. Waldhauer, I. and Steinle, A., Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006. 66: 2520-2526.
26. Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D. and Tabi, Z., Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 2008. 180: 7249-7258.
27. Cerboni, C., Ardolino, M., Santoni, A. and Zingoni, A., Detuning CD8+ T lymphocytes by down-regulation of the activating receptorNKG2D: role of NKG2D ligands released by activated T cells. Blood 2009. 113: 2955-2964.
28. Osaki, T., Saito, H., Yoshikawa, T., Matsumoto, S., Tatebe, S., Tsujitani, S. and Ikeguchi, M., Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin. Cancer Res. 2007. 13: 382-387.
29. von Lilienfeld-Toal, M., Frank, S., Leyendecker, C., Feyler, S., Jarmin, S., Morgan, R., Glasmacher, A. et al., Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol. Immunother. 2010. 59: 829-839.
30. Pende, D., Rivera, P., Marcenaro, S., Chang, C. C., Biassoni, R., Conte, R., Kubin, M. et al., Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002. 62: 6178-6186.
31. Paolini, R., Molfetta, R., Piccoli, M., Frati, L. and Santoni, A., Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proc. Natl. Acad. Sci. USA 2001. 98: 9611-9616.
32. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999. 285: 727-729.
33. Wu, J., Song, Y., Bakker, A. B., Bauer, S., Spies, T., Lanier, L. L. and Phillips, J. H., An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999. 285: 730-732.
34. Upshaw, J. L., Arneson, L. N., Schoon, R. A., Dick, C. J., Billadeau, D. D. and Leibson, P. J., NKG2D-mediated signaling requires a DAP10-bound Grb2- Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 2006. 7: 524-532.
35. Kim, H. S., Das, A., Gross, C. C., Bryceson, Y. T. and Long, E. O., Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 2010. 32: 175-186.
36. Kassenbrock, C. K. and Anderson, S. M., Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J. Biol. Chem. 2004. 279: 28017-28027.
37. Huang, F. and Gu, H., Negative regulation of lymphocyte development and function by the Cbl family of proteins. Immunol. Rev. 2008. 224: 229- 238.
38. Gasparrini, F., Molfetta, R., Santoni, A. and Paolini, R., Cbl family proteins: balancing FceRI-mediated mast cell and basophil activation. Int. Arch. Allergy Immunol. 2011. 156: 16-26.
39. Molfetta, R., Gasparrini, F., Peruzzi, G., Vian, L., Piccoli, M., Frati, L., Santoni, A. et al., Lipid raft-dependent FcepsilonRI ubiquitination regulates receptor endocytosis through the action of ubiquitin binding adaptors. PLoS One 2009. 4: e5604.
40. Champsaur, M., Beilke, J. N., Ogasawara, K., Koszinowski, U. H., Jonjic, S. and Lanier, L. L., Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1. J. Immunol. 2010. 185: 157-165.
41. Hanaoka, N., Jabri, B., Dai, Z., Ciszewski, C., Stevens, A. M., Yee, C., Nakakuma, H. et al., NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J. Immunol. 2010. 185: 5732-5742.
42. Roda-Navarro, P., Vales-Gomez, M., Chisholm, S. E. and Reyburn, H. T., Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc. Natl. Acad. Sci. USA 2006. 103: 11258-11263.
43. Roda-Navarro, P. and Reyburn, H. T., The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation. J. Biol. Chem. 2009. 284: 16463-16472.
44. Schmidt, M. H. and Dikic, I., The Cbl interactome and its functions. Nat. Rev. Mol. Cell. Biol. 2005. 6: 907-918.
45. Masilamani, M., Peruzzi, G., Borrego, F. and Coligan, J. E., Endocytosis and intracellular trafficking of human natural killer cell receptors. Traffic. 2009. 10: 1735-1744.
46. Horng, T., Bezbradica, J. S. and Medzhitov, R.,NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat. Immunol. 2007. 8: 1345-1352.
47. Eleme, K., Taner, S. B., Onfelt, B., Collinson, L. M., McCann, F. E., Chalupny, N. J., Cosman, D. et al., Cell surface organization of stressinducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J. Exp. Med. 2004. 199: 1005-1010.
48. Dustin, M. L. and Depoil, D., New insights into the T cell synapse from single molecule techniques. Nat. Rev. Immunol. 2011. 11:672-684.
49. Brown, A. C., Oddos, S., Dobbie, I. M., Alakoskela, J. M., Parton, R. M., Eissmann, P., Neil, M. A. et al., Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by superresolution microscopy. PLoS Biol. 2011. 9:e1001152.
50. Liu, D., Bryceson, Y. T., Meckel, T., Vasiliver-Shamis, G.,Dustin,M. L.and Long, E. O., Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity 2009. 31: 99-109.
51. Zingoni, A., Sornasse, T., Cocks, B. G., Tanaka, Y., Santoni, A. and Lanier, L. L., Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 2004. 173: 3716-3724.
52. Maasho, K., Marusina, A., Reynolds, N. M., Coligan, J. E. and Borrego, F., Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system. J. Immunol. Methods. 2004. 284: 133-140.
53. Gasparrini, F., Molfetta, R., Quatrini, L., Frati, L., Santoni, A. and Paolini, R., Syk-dependent regulation of Hrs phosphorylation and ubiquitination upon FceRI engagement: impact on Hrs membrane/cytosol localization. Eur. J. Immunol. 2012. 42: 2744-2753.
54. Peruzzi, G., Molfetta, R., Gasparrini, F., Vian, L., Morrone, S., Piccoli, M., Frati, L. et al., The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway. J. Immunol. 2007. 179: 2089-2096.
55. Capuano, C., Paolini, R., Molfetta, R., Frati, L., Santoni, A. and Galandrini, R., PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway. Blood. 2012. 119: 2252-2262.